A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study

@article{Tellingen1998ACP,
  title={A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study},
  author={Olaf van Tellingen and Cornelis J. A. Punt and Ahmad Awada and D. J. Theo Wagener and Martine J. Piccart and Yvonne de Groot and Larry J. Schaaf and Roland E. C. Henrar and Willem J. Nooijen and Jos H. Beijnen},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1998},
  volume={41},
  pages={377-384}
}
We investigated the pharmacokinetic behavior of carzelesin in 31 patients receiving this drug by 10-min intravenous infusion in a Phase I clinical trial, which was conducted at institutions in Nijmegen (institution 1) and Brussels (institution 2). The dose steps were 24, 48, 96, 130, 150, 170, 210, 250, and 300 μg/m2. Carzelesin is a cyclopropylpyrroloindole prodrug that requires metabolic activation via U-76,073 to U-76,074. The lower limit of quantitation (LLQ) of the high-performance liquid… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given on a daily 5 schedule

  • I Wol, K Bench, +7 authors C Sessa
  • Clin Cancer Res
  • 1996
1 Excerpt

Therapeutic ecacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors

  • PJ Houghton, PJ Cheshire, JD IIHallman, JA Houghton
  • Cancer Chemother Pharmacol
  • 1995
1 Excerpt

Location of the site of thermally induced strand breakage and analysis of DNA sequence speci ® city

  • GJ Shamdas, DS Alberts, +5 authors RH Earhart
  • 1994

Plasma pharmacokinetics of carzelesin (U-80,244) and metabolites (U-76,073, U-76,074) in mice and rats

  • O vanTellingen, JH Beijnen, +4 authors GE Padbury
  • Ann Oncol 5 [Suppl
  • 1994
3 Excerpts

Similar Papers

Loading similar papers…